Hutchmed (HCM) stock rises despite a 2024 revenue miss as a cancer drug combo it developed with Innovent Biologics (IVBYI) ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Chinese-based Innovent Biologics and HUTCHMED are eyeing approval for their cancer combination after a joint Phase II/III ...

Anemia and low performance status predict worse survival and greater risk for treatment failure in low-intermediate risk vs ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell carcinoma.

(1−5) Despite these strides, the efficacy of existing immunotherapies is hampered by the immunosuppressive microenvironment of “cold” triple-negative breast cancer (TNBC), marked by inadequate T-cell ...

Serum amylase and lipase levels were raised (228 U/L and 616 U/L respectively), liver and renal function tests ... small round blue cell in the papillary as well as reticular dermis. Epidermotropism ...

Purpose: Type 1 diabetes mellitus (T1DM), as an autoimmune disease, can increase susceptibility to clear cell renal cell carcinoma (ccRCC ... of the hub genes were confirmed via RT-qPCR and IHC, and ...

A phase I dose escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear cell renal cell carcinoma. March 7, 2025 Immunotherapy in metastatic renal cell carcinoma: Insights ...

The Business Research Company The Business Research Company's Renal Cell Carcinoma Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Releas... ...